Company Profile

Silvec Biologics Inc
Profile last edited on: 1/10/2023      CAGE: 8LAV6      UEI: ZH7KBVHXP1C3

Business Identifier: RNA therapies designed to inoculate trees, vine and bush against diseases, eliminating the need for genetic modification
Year Founded
2019
First Award
2021
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

9600 Gudelsky Drive
Rockville, MD 20850
   (225) 302-3440
   info@silvec.com
   www.silvecbiologics.com
Location: Single
Congr. District: 08
County: Montgomery

Public Profile

Founded by a known plant pathogen expert and geneticist, Silvec provides best-in-class RNA-based solutions for long-lived plants. Effectively, the firm is vaccinating trees against most diseases, enhancing the plant's ability to grow in marginal soils, and improving their product quality. A range of factors - international travel, climate change etc is fuelling an exponential spread of invasive pathogens - killing or depleting trees, bushes and vines in all sectors of agriculture, timber and forestry. With the Silvec Biologic's RNA tree-focused product administered to seedlings and mature trees alike, a single application provides a lifetime of protection without altering the plant’s genome. The firm's product can also provide a platform for a complete suite of trait-enhancements - potentially enabling plants to tolerate conditions related to climate change. The platform can deliver various enhancements to include carbon capture, drought and flood tolerance, increased growth rates, reduced chemical inputs, delayed post-harvest rot, and enhanced disease resistance callose downregulation.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 2 NSF $1,250,929
Project Title: Using a novel RNA therapy to immunize trees and vines against deadly bacteria
2022 2 USDA $824,964
Project Title: Defeating Boytrytis in grapevines with siRNAs

Key People / Management

  Rafael Simon -- President andCo-Founder

  Julie Friedman Steele -- Co-Founder and Chief Strategy Officer

  Feng Gao -- Assistant Research Scientist

  Anne Elizabeth Simon -- Chief Technical Officer

  Stephen Yang -- Principal Scientist

Company News

There are no news available.